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Many endoscopic imaging modalities have been developed and introduced into clinical practice to enhance the diagnostic
capabilities of upper endoscopy. In the past, detection of dysplasia and carcinoma of esophagus had been dependent on biopsies
taken during standard white-light endoscopy (WLE). Recently high-resolution (HR) endoscopy enables us to visualize esophageal
mucosa but resolution for glandular structures and cells is still low. Probe-based confocal laser endomicroscopy (pCLE) is a new
promising diagnostic technique by which details of glandular and vascular structures of mucosal layer can be observed. However,
the clinical utility of this new diagnostic tool has not yet been fully explored in a clinical setting. In this paper we will highlight this
new technique for detection of esophageal dysplasia and carcinoma from a clinical practice perspective.
1.Introduction
Esophageal adenocarcinoma has the fastest growing inci-
dence rate (300% increase over the past 4 decades) [1–
3], and the risk of patients with Barrett’s Esophagus (BE)
of developing adenocarcinoma is 30–120 times greater. BE
is a change in the distal esophageal epithelium of any
length that can be recognized as columnar-type mucosa at
endoscopy and is conﬁrmed to have intestinal metaplasia
by biopsy of the tubular esophagus [4]. The currently
accepted paradigm correlates the risk of progression to the
grade of dysplasia as there is evidence that progression
occurs in an orderly fashion from no dysplasia to low-grade
dysplasia (LGD) to high-grade dysplasia (HGD) followed by
earlyesophagealadenocarcinoma[5].Inadditionesophageal
adenocarcinoma has a poor survival rate (<5% at ﬁve years)
due to a late diagnosis, to an early vascular and lymphatic
inﬁltration and to low vascularization of neoplastic tissue,
which leads to a low response to chemotherapy of the tumor
[4].
Since BE is considered the most important risk factor for
the development of esophageal adenocarcinoma, assuming
that the detection of mucosal dysplasia is critically important
inpatientswithBarrett’soesophagus,becauseearlydiagnosis
can prevent the progression to invasive carcinoma, interna-
tional societies of gastrointestinal diseases suggest keeping
patients in endoscopy surveillance program [5–7].
However, surveillance endoscopy has several limitations
because dysplastic changes occurring in BE are not easily
identiﬁable by standard endoscopy.
In the last decades, many technologic advances have been
done in the ﬁeld of endoscopic imaging, through HR en-
doscopy to magniﬁcation endoscopy to virtual chromoen-
doscopy, in order to achieve a better visualisation of mucosal
layer and to distinguish neoplastic versus nonneoplastic
tissue. But even if good, new techniques are not strong
enough to replace biopsies. Consequently, the current stan-
dard of endoscopic practice is to take multiple biopsies
because there are no features on standard or HR endoscopy
that distinguish Barrett’s glandular metaplasia, dysplasia,
or early-stage neoplasia. However the accuracy of standard
white light endoscopy (WLE) and random biopsies is low
and may fail to detect neoplastic lesions [7]. Moreover
biopsies obtained using this technique are prone to sampling
error, and interobserver agreement is low even between
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[8, 9]. This results often in: (1) delay in reaching the ﬁnal
diagnosis and the decision of the correct and best treat-
ment, (2) increased costs in pathology procedures, and (3)
repeated procedures. In addition, sensitivity and speciﬁcity
of histology are variable for diﬃculty to reach specimen
adequacy. Moreover the presence of inﬂammation or ulcers
could alter the mucosal architecture and give some false
negative/positive results to pathology examination [10–14].
A multiple biopsies protocol could also interfere with next
therapeutic steps; endoscopic mucosal resection (EMR) or
endoscopic submucosal dissection (ESD) could be more
diﬃcult without adequate “lifting sign” due to scar tissue
after repeated biopsies.
Nevertheless another important limitation of histology is
that it is a postmortem analysis and it is not able to give us
information about in vivo processes (blood ﬂow).
Confocal laser endomicroscopy (CLE), a recent advance
of endoluminal imaging, allows an in vivo visualization of
mucosal layer with a detailed visualization of tissue and
subcellular structures with magniﬁcation up to 1000 times.
Since 2004 many papers, about the potential role of this new
technique, have been published, and many studies have been
introduced to validate this technique.
CLE has the potential to anticipate the ﬁnal diagnosis
(neoplastic versus nonneoplastic) and potentially to guide
next therapeutic steps in clinical practice without the delay
of a pathology response. Moreover it oﬀers the possibility
to study mucosal layer to a micron resolution giving us an
“optical biopsy”. However, other technologies, such as nar-
row band imaging (NBI), autoﬂuorescence imaging (AFI),
and chromoendoscopy, are needed as “red-ﬂag” techniques
to initially detect and localize suspicious areas.
One of the potentially future applications of pCLE is
about a role in in vivo study of physiologic and pathologic
processes, like inﬂammation or angiogenesis in healthy or
neoplastic tissue [15].
Currently two devices are available and approved by
European Medicines Agency (EMA) and Food and Drug Ad-
ministration (FDA) to perform CLE: one system is inserted
in tip of the scope (eCLE, Pentax Corporation, Tokyo, Japan)
and one, a probe-based system, is a separate device from
the endoscope but able to be introduced in the working
channel of any standard endoscope (pCLE, Cellvizio, Mauna
KeaTech, Paris, France).
eCLE. In this system, the miniaturized confocal scanner has
been integrated into the distal tip of a new endoscope. A
blue laser light source delivers an excitation wavelength of
488nm and light emissions detected at >505nm. Successive
points within the tissue are scanned in a raster pattern along
X-axis and Y-axis to construct serial en face optical section
of 475 × 475µm at user-controlled variable imaging depth.
The optical slice thickness is 7µm with a lateral resolution
of 0.7µm. Images on the screen approximate a 1000-fold
magniﬁcationofthetissueinvivo[16].Theadvantageofthis
system is that the working channel of the scope is free, and it
canbeusedfortargetbiopsies orforcombinedenhancement
techniques such as chromoendoscopy. The limit of this
system is that the calibre of the scope is bigger than a
standard 11.8mm upper scope and is stiﬀ. Moreover the lens
of the scope is not combined with HR software and virtual
chromoendoscopy or other system (ISCAN).
pCLE. this system can be used through the working chan-
nel of any standard endoscope (colonoscope, gastroscope,
cholangioscope, bronchoscope, and ureteroscop, etc). The
advantage of this probe-based CLE is the versatility of the
system and the possibility to combine it with other advanced
“red ﬂag” imaging modalities such as virtual chromoen-
doscopy or magniﬁcation. Scanning rates is 12 images/sec.
The limits of this system pCLE are the slightly low power
resolution compared to eCLE (1mm versus 0.7mm) and a
small ﬁeld of view (240–600mm). So pCLE system is not
well suited to surveying large areas of tissue such as long
segments of BE and should ideally be combined with a red-
ﬂag technique for classiﬁcation of tissue in a site already
detected by enhanced endoscopy. However Mauna Kea has
developed a postacquisition speciﬁcally-developed software
(“mosaicing”) to paste images together and to obtain images
similar to histology specimen.
2. Classiﬁcation
An important issue for a new imaging technique is the stan-
dardization of terminology and classiﬁcation of images. The
ﬁrst published classiﬁcation about confocal imaging was the
“Mainz classiﬁcation” based on eCLE [17]. However, due to
several technical diﬀerences between pCLE and e-CLE, in
2011 a new classiﬁcation based on pCLE has been published
afteraconsensusofpCLEexpertsheldinMiamiin2009[18].
pCLE shows detailed images including squamous epithe-
lium, glandular architecture, crypts, columnar cells, goblet
cells, and capillaries with red blood cells. In patients with a
normal squamous epithelium pCLE shows ﬂat cells without
crypts, or villi, bright vessels within capillary loops. In case
of BE diagnosis, pCLE shows the villiform architecture,
columnar cells, and the presence of goblet cells (Figure 1).
If the BE is complicated with dysplasia pCLE shows villiform
structureswith dark, irregularly thickened epithelial borders,
dilated irregular vessels. In case of adenocarcinoma disorga-
nized/loss of villiform structure and crypts dark columnar
cells and dilated irregular vessels are found (Figure 2)[ 18].
3.Barrett’sEsophagusSurveillance
One of the ﬁrst and major clinical applications of pCLE is BE
surveillanceor,withatherapeuticapproach,thedeﬁnitionof
lesion’s margin before EMR or ESD.
First published data (noncontrolled trials) showed that
pCLE was able to detect intraepithelial neoplasia with a
sensitivity of 75% and speciﬁcity of 89–91% [19]. In the
same paper, ranking study population for disease-risk, in the
low-risk group population, pCLE has a NPV nearly 98.8%
suggesting the possibility to avoid random biopsies. How-
ever, a false-positive rate for suspected dysplasia of 64.3%
using endomicroscopy was commented, and the authorsGastroenterology Research and Practice 3
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Figure 1: Normal Barrett’s mucosa at pCLE: Villiform structure
with goblet cell and regular epithelial lining.
20 µm
Figure 2:DysplasticBarrett’smucosa.Villiformstructurewithdark
and irregularly thickened epithelial lining.
replied that the study was not designed to calculate the
performancecharacteristics(sensitivity,speciﬁcity,accuracy)
[20]. In a pilot study by Pohl et al. the author evaluated
the preliminary accuracy of pCLE for high-grade dysplasia
(HGD) and adenocarcinoma in BE patients. They evaluated
296 sites in a 38-patient group. The overall accuracy of pCLE
was 88% to 93% with a sensitivity of 75% to 80% and
speciﬁcity of 89% to 94%, a PPV of 44.4%, and a NPV of
98.8% [21]. Kiesslich et al. using the eCLE system achieved
an accuracy of 96.8% in BE metaplasia diagnosis and an
accuracy of 97.4% in neoplasia diagnosis [17].
Another study by Bajbouj et al. [22] did not conﬁrm
these data, and the authors explained the diﬀerences with
previous results with the low frequency of neoplasia detected
in the study and secondly to strict adherence with diagnostic
criteria for neoplasia in their data. The prevalence of
neoplasia was lower than in the published data using the
CLE system or other studies evaluating diﬀerent imaging
modalities, which have described prevalence of HG dysplasia
or early cancers ranging between 24% and 59%. The authors
also face the problem of overinterpretation in those studies,
and the possibility of false positive pCLE ﬁndings increases
[20].
Dunbar et al. [19] also demonstrated an increased yield
of neoplasia compared to 4-quadrant biopsy protocol. Al-
though the sensitivity of pCLE found in this study was
lower than found in some previous studies, this study used
a real-time prediction of histology by a great number of
endoscopists from diﬀerent Endoscopic Academic centers,
whichuseddiﬀerent criteria in pCLE imaging interpretation,
which may have led to variable results.
Recently Sharma et al. published the ﬁrst international
multicenter prospective randomized controlled trial [23].
The authors demonstrated signiﬁcantly improved sensitivity
in detection of HGD/EC using pCLE. The study involved
5 international centers, and 122 patients were enrolled. Of
the enrolled patients, 21 were excluded from the analysis. A
twofold increased sensitivity in detections of HGD/EC for
HD-WLE compared to HD-WLE or pCLE (34.2% to 68.3%,
resp.)wasshown.Thistranslatedinto41additionallocations
with HGD/EC being identiﬁed when pCLE was used in
conjunction with HD-WLE compared with HD-WLE alone
[23].
4.Barrett’sEsophagus Treatment
Another recent application of confocal endomicroscopy is a
role in therapeutic endoscopic procedures. The management
of BE with neoplasia (HGD/“early cancer”) ranges from
surgery to endoscopic treatment and is evolving to include
multiple endoscopic modalities in order to increase the
rates of esophagus-sparing therapies. Recently, the trend
is not only to treat the dysplastic BE but also to eradi-
cate the remaining at-risk Barrett’s epithelium to prevent
metachronous and synchronous lesions. Endoscopic thera-
pies include both tissue-acquiring (EMR, ESD) and non-
tissue-acquiringtherapies(RFAandphotodynamictherapy).
The results of the above-mentioned therapies are very
diﬀerent in the published series; EMR demonstrated a long-
term experiences and good results in terms of radicality at
the expense of high complications rates such as perforations
and strictures [24, 25]. RFA and cryotherapy oﬀer promising
results, though the latter still lacks signiﬁcant follow-up
time [26]. But in this great number of emerging therapies,
the appropriate selection of an endoscopic modality for
the treatment of a lesion in clinical practice is based upon
endoscopist’s experience and new technologies’ availability.
pCLE can play a role in (a) localization of lesions and
prediction of pathology, (b) in targeting biopsies and resec-
tions in surveillance and treatment, and (c) in the choice
of therapy to use. Konda et al. recently published a case
series [27] showing a possible role of pCLE in therapeutic
endoscopy. This case series illustrates a range of cases in
which CLE was used during the procedure and oﬀered the
chance of providing real-time information during endo-
scopic treatment or follow-up. Thus, the endoscopist may4 Gastroenterology Research and Practice
have endomicroscopic information, and in the future pCLE
could be used to tailor BE management strategy between
surveillance, biopsies, ablation, or resection-based strategies.
5. InterobserverAgreementandLearningCurve
Issuestoconsiderbeforeintroducinganewtechniqueinclin-
ical practice include the learning curve for the endoscopist
and interobserver agreement.
Wallace et al. [28] evaluated the accuracy and inter-
observer agreement of 9 international endoscopists in pCLE
inpatientswithBE-associateddysplasia.Theoverallaccuracy
of pCLE for the diagnosis of HGD was 90.5%, sensitivity
88%, and speciﬁcity 94%. If endoscopist had previous expe-
rience in endomicroscopy imaging interpretation, the overall
accuracy was of 97%, sensitivity 94%, and speciﬁcity of
100%. The overall interobserver agreement was 0.72; 95%
(CI 0.57–0.85). A matter of contention is the need of a real-
time interpretation that may be diﬀerent from reviewing
sequences after image acquisition.
6. Conclusions
The promising results recently published are potentially
changing the role of endoscopist into an “endomicroscopist”.
However, for any emerging technique, more data are needed
to conﬁrm the results in clinical setting, to evaluate the
possible increased diagnostic accuracy of HR endoscopy and
the possibility to reduce the missing rate of dysplastic BE in
surveillance program. Another issue will be the applicability
of a new technique outside research program and the costs,
if applied, in surveillance program.
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